Boston Scientific stock gets a lower Citigroup price target

Published on 10/07/2026 at 16:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Boston Scientific stock saw Citigroup cut its target from USD 50.00 to USD 48.00 on October 5, 2026. Q2 revenue reached USD 5.44 billion, up 7.5 percent year over year.

Schwarz-Weiß-Reportage: Büroangestellte treten durch Drehtüren eines Bürogebäudes — Boston Properties US1011371077 dokumentiert Angestellte beim Betreten eines klassischen amerikanischen Büroturms in der Innenstadt, Illustration mit AI erstellt.

Boston Scientific stock (ISIN US1011371077) was trading at USD 41.97 on the NYSE on October 7, 2026, down 0.52 percent at 10:48 a.m. ET. The immediate catalyst is Citigroup's price-target reduction from USD 50.00 to USD 48.00, reported by MarketBeat on October 5, 2026.

Citigroup trims its target

Citigroup maintained a Neutral rating while lowering its Boston Scientific target by USD 2.00. At USD 41.97, the new USD 48.00 target lies 14.37 percent above the stock price, leaving the market to weigh recovery prospects against the company's recent execution pressure.

The broader analyst picture is less negative than the single-house action. MarketBeat reported a Moderate Buy consensus based on 23 Buy, five Hold and two Sell ratings, with an average price target of USD 67.88. That consensus target lies 61.73 percent above the October 7 price.

Q2 revenue rose 7.5 percent

Boston Scientific's second-quarter 2026 revenue reached USD 5.44 billion, up 7.5 percent from the year-earlier quarter, while adjusted EPS came in at USD 0.86 against a USD 0.83 consensus estimate, according to MarketBeat. The revenue comparison gives investors a stronger operating marker than the target revisions alone.

Boston Scientific also set third-quarter 2026 adjusted EPS guidance at USD 0.800-0.820 and full-year 2026 adjusted EPS guidance at USD 3.280-3.320, as reported by MarketBeat. The range makes the October reporting date particularly important for testing whether the business can stabilize after the guidance pressure discussed by analysts.

October 28 sets the next test

Boston Scientific is scheduled to report its next earnings update on October 28, 2026, according to Yahoo Finance. The release is expected to provide the next quantified update on the effect of the cyberattack on sales and adjusted earnings guidance.

NYSE quote nears yearly low

At 10:48 a.m. ET on October 7, 2026, Boston Scientific was last at USD 41.97 on the NYSE, 0.38 percent above its 52-week low of USD 41.81; volume stood at 4,307,373 shares and market capitalization at USD 62.4 billion.